Related Experiment Videos
Development of drug tachyphylaxis in asthmatic patients treated with beta-adrenergic drugs
I Herjavecz1, G Böszörményi-Nagy, A Szeitz
1Clinical Pharmacological Group, National Korányi Institute for TBC and Pulmonology, Budapest, Hungary.
Abstract:
The development of drug tolerance in two groups of asthmatics treated with beta-adrenergic bronchodilators was studied by respiratory function methods. During one-year treatment with conventional therapeutic doses of selective beta-2-receptor stimulant aerosols, none of the patients showed subsensitivity to the bronchodilatory effect of terbutaline. Dose-response curves were plotted upon the inhalation of salbutamol in two-week intervals in patients treated with betamimetics. There was no decrease in the airways beta-adrenergic receptor function as compared to the untreated control group. The results show that prolonged treatment with therapeutic doses of inhaled beta-adrenergic bronchodilators does not result in drug tachyphylaxis, which is in accord with the clinical experience that there is no loss of effect of the preparations during their continuous administration.
Insights
Long-term use of inhaled beta-adrenergic bronchodilators for asthma did not lead to reduced effectiveness. Studies showed no drug tolerance or loss of therapeutic effect in patients using these medications.
Area of Science:
- Pharmacology
- Respiratory Medicine
- Clinical Therapeutics
Background:
- Beta-adrenergic bronchodilators are commonly prescribed for asthma management.
- Concerns exist regarding the potential development of drug tolerance (tachyphylaxis) with prolonged use.
Purpose of the Study:
- To investigate the development of drug tolerance in asthmatic patients treated with beta-adrenergic bronchodilators.
- To assess the long-term effects of inhaled selective beta-2-receptor stimulants on airway responsiveness.
Main Methods:
- Respiratory function tests were employed to monitor patients.
- Dose-response curves for salbutamol were plotted at two-week intervals.
- Comparison was made with an untreated control group.
Main Results:
- No subsensitivity to terbutaline was observed in patients treated for one year with therapeutic doses of beta-2-receptor stimulant aerosols.
- Airway beta-adrenergic receptor function remained unchanged compared to the control group.
- Prolonged treatment did not induce tachyphylaxis.
Conclusions:
- Continuous, therapeutic administration of inhaled beta-adrenergic bronchodilators does not result in a loss of drug effect.
- Findings align with clinical observations of sustained efficacy during long-term use.